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OBJECTIVES This study was designed to evaluate B-type natriuretic peptide (BNP) for risk assessment and
clinical decision making over a range of cut points, alone and with cardiac troponin I (cTnI),
in patients with non–ST-elevation acute coronary syndromes (ACS).
BACKGROUND B-type natriuretic peptide holds promise for risk stratification. Additional evidence regarding
optimal decision limits, use in combination with troponin, and use in targeting therapy is
needed before acceptance into clinical use for ACS.
METHODS We evaluated BNP at baseline in 1,676 patients with non–ST-elevation ACS randomized to
early invasive versus conservative management.
RESULTS Patients with elevated BNP (80 pg/ml; n  320) were at higher risk of death at seven days
(2.5% vs. 0.7%, p  0.006) and six months (8.4% vs. 1.8%, p  0.0001). The association
between BNP and mortality at six months (adjusted odds ratio [OR] 3.3; 95% confidence
interval [CI] 1.7 to 6.3) was independent of important clinical predictors, including cTnI and
congestive heart failure (CHF). Patients with elevated BNP had a fivefold higher risk of
developing new CHF by 30 days (5.9% vs. 1.0%, p  0.0001). B-type natriuretic peptide
added prognostic information to cTnI, discriminating patients at higher mortality risk among
those with negative (OR 6.9; 95% CI 1.9 to 25.8) and positive (OR 4.1; 95% CI 1.9 to 9.0)
baseline cTnI results. No difference was observed in the effect of invasive versus conservative
management when stratified by baseline levels of BNP (pinteraction  0.6).
CONCLUSIONS Elevated BNP (80 pg/ml) at presentation identifies patients with non–ST-elevation ACS
who are at higher risk of death and CHF and adds incremental information to cTnI.
Additional work is needed to identify therapies that may reduce the risk associated with
increased BNP. (J Am Coll Cardiol 2003;41:1264–72) © 2003 by the American College of
Cardiology Foundation
B-type natriuretic peptide (BNP) is a cardiac neurohormone
that is synthesized in ventricular myocardium and released
in response to increased ventricular wall stress (1–3). Its
diverse actions include natriuresis, vasodilation, inhibition
of the renin-angiotensin-aldosterone system, and inhibition
of sympathetic nerve activity (4). First studied as a diagnos-
tic and prognostic marker among patients with congestive
heart failure (CHF) (5–7), BNP was subsequently found to
predict outcomes in patients with acute myocardial infarc-
tion (MI) (8,9). Specifically, when measured between one
and four days after presentation with transmural infarction,
an elevated plasma concentration of BNP was associated
with increased mortality risk, independently of left ventric-
ular function (8,10,11). We recently extended these findings
across the spectrum of patients with acute coronary syn-
dromes (ACS), including those with unstable angina (UA),
among whom elevated levels of BNP predicted a twofold to
threefold higher risk of death by 10 months (12). Together,
these data suggest that measurement of BNP in patients
presenting with suspected ACS could be an important
addition to our current tools for risk stratification.
Before considering BNP for routine clinical application in
ACS, consistent findings from independent data sets are
needed. Moreover, the optimal decision limits for prognos-
tic evaluation must be defined, and careful assessment of the
utility of BNP in combination with cardiac troponin is
required. Lastly, the utility of BNP for directing therapeutic
decision making requires testing. We thus evaluated the
predictive capacity of BNP over a range of clinical thresh-
olds, alone and in combination with cardiac troponin I
(cTnI), among patients with non–ST-elevation ACS en-
rolled in the Treat Angina with Aggrastat and Determine
Cost of Therapy with an Invasive or Conservative Strategy
(TACTICS)-Thrombolysis In Myocardial Infarction
(TIMI) 18 trial (13). We also assessed whether BNP is
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useful in identifying patients who will derive greater benefit
from an early invasive management strategy.
METHODS
Study population and treatment. A total of 2,220 patients
were enrolled in TACTICS-TIMI 18 between December
18, 1997, and December 22, 1999. The study design and
primary results have been described previously (13). Patients
18 years old were eligible for enrollment if they experi-
enced UA within the preceding 24 h, were candidates for
coronary revascularization, and had at least one of the
following: ST segment depression (0.05 mV) or transient
ST elevation, T wave (0.3 mV) inversion in 2 leads,
elevated cardiac markers of necrosis, or documented coro-
nary disease. Exclusion criteria included persistent ST-
segment elevation, recent revascularization, factors associ-
ated with increased risk of bleeding, severe CHF or
cardiogenic shock, important systemic disease, or serum
creatinine 2.5 mg/dl.
Patients were treated with aspirin, intravenous unfrac-
tionated heparin, and tirofiban (Merck and Co., West
Point, Pennsylvania) and were randomized to an early
invasive or conservative strategy. Patients in the early
invasive strategy were to undergo coronary angiography
between 4 and 48 h after randomization, and revasculariza-
tion when feasible based on coronary anatomy. Patients in
the conservative strategy were treated medically and were to
undergo coronary angiography and revascularization only if
they manifested recurrent ischemia at rest or with provoc-
ative testing. The study protocol was approved by the
institutional review boards of each participating hospital,
and patients provided written informed consent.
End points. Patients were followed up for six months for
the development of recurrent clinical events, including
death from any cause, new or recurrent MI, rehospitaliza-
tion for ACS, and new or worsening CHF. Each of these
end points, except new/worsening CHF, were adjudicated
by an independent clinical end points committee, blinded to
treatment assignment. The index diagnosis was established
by the investigator based on local electrocardiographic and
laboratory data.
BNP testing. The protocol specified that blood samples be
obtained at enrollment by trained study personnel in citrate-
anticoagulated tubes and plasma isolated within 60 min of
sample acquisition. Plasma samples were stored at20°C or
colder at the enrolling site until shipped to the TIMI
Biomarker Core Laboratory, where they were maintained at
80°C. Aliquots were shipped frozen to Biosite Incorpo-
rated (San Diego, California), where they were thawed and
analyzed using an established immunoassay (12) by person-
nel blinded to treatment allocation and clinical outcomes.
The primary decision limit of 80 pg/ml was pre-specified
based on our previous work with this assay (12).
Levels of cTnI were measured in the TIMI Biomarker
Core Laboratory using the ACS:180 Chemiluminescence
cTnI Immunoassay (Bayer Diagnostics, Tarrytown, New
York) (14). The minimum detectable concentration is 0.03
ng/ml. A prognostic decision limit of 0.1 ng/ml was used for
all analyses based on previous work with this assay (15).
Statistical methods. Plasma concentrations of BNP are
described as the median and interquartile range. The base-
line characteristics of patients with and of those without
elevated levels of BNP were compared using the Wilcoxon
Rank Sums test for continuous variables and the chi-
squared test for categorical variables. Correlation coefficients
reported between continuous variables are based on a
non-parametric method (Spearman correlation). Analysis of
findings from the TIMI Angiographic Core Laboratory
were performed for the subset of patients participating in
the TACTICS-TIMI 18 angiographic substudy. Data re-
garding the number of diseased coronary arteries were based
on local interpretation in all patients undergoing angiogra-
phy.
The univariate association between BNP and clinical
outcomes, alone and stratified by cTnI, was evaluated using
the chi-square test for dichotomized comparisons and the
chi-square test for trend across BNP quartiles. The log-rank
test was performed for the Kaplan-Meier probability esti-
mates (Fig. 1). Using logistic regression, the relationship
between BNP (dichotomized) and outcomes was adjusted
for the effects of age, gender, diabetes, ST-segment depres-
sion on the presenting ECG, history of CHF, evidence of
heart failure (HF) at presentation, and baseline cTnI result.
Age was treated as a continuous variable. ST depression and
baseline cTnI were dichotomized at thresholds of 0.05
mV and 0.1 ng/ml, respectively. Clinical follow-up
through six months was complete among99% of patients,
supporting the use of logistic regression as opposed to Cox
proportional hazard modeling. The primary cut point for
BNP (80 pg/ml) was pre-specified based on our previous
work with this assay (12). In addition, an exploratory
analysis of the predictive capacity of BNP at thresholds
across the range of 40 to 160 pg/ml was performed using
logistic regression. The relative predictive value at each
threshold was assessed using the chi-squared values and
adjusted risk relationships from logistic regression.
Testing for heterogeneity in the effect of the invasive
Abbreviations and Acronyms
ACS  acute coronary syndrome(s)
BNP  B-type natriuretic peptide
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CI  confidence interval
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HF  heart failure
MI  myocardial infarction
NSTEMI  non–ST-elevation myocardial infarction
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strategy between patients with and those without elevated
levels of BNP was performed using logistic regression with
terms for the main effects and for the interaction of BNP
status with treatment allocation. Analyses were performed
using STATA v7-intercooled (STATA Corp., College
Station, Texas). A p value (two-tailed) 0.05 was consid-
ered statistically significant.
RESULTS
A total of 1,676 samples were available for determination of
BNP levels at enrollment in TACTICS-TIMI 18. The
baseline characteristics of those without available samples
were similar to those included in this substudy (data not
shown). Median (25th to 75th percentile) levels of BNP
were 20 pg/ml (5 to 54 pg/ml) and 38 pg/ml (10 to 81
pg/ml) in patients with index diagnoses of UA and non–
ST-elevation myocardial infarction (NSTEMI), respec-
tively. The plasma concentration of BNP exceeded 80 pg/ml
in 25.2% (n  153) of patients presenting with NSTEMI,
15.6% (n 167) of patients diagnosed with UA, and 10.1%
(n  67) of those with baseline levels of cTnI 0.1 ng/ml.
Elevated levels of BNP were detected among 13.6% (n 
135) of those with UA and no history or current evidence of
HF.
Patients with elevated levels of BNP were older, more
often female, and more likely to have a history of HF and
diabetes (Table 1). At presentation, patients with elevated
BNP more frequently had ST-segment depression and
tachycardia (100 beats/min). There was no association
between elevated levels of BNP and a history of prior MI. A
Figure 1. Kaplan-Meier estimates of the probability of death (A) and death or congestive heart failure (CHF) (B) through six months among patients with
baseline concentration of B-type natriuretic peptide (BNP) 80 pg/ml and 80 pg/ml. The p values are based on the log-rank test.
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modest correlation between baseline levels of BNP and peak
creatine kinase-MB (CK-MB) was evident (  0.27, p 
0.001). Patients with elevated BNP were more likely to have
multi-vessel (2) coronary artery disease (74% vs. 60%, p
0.0001). In the sub-group of patients with films submitted
for interpretation by the TIMI Angiographic Core Labo-
ratory (n  416), similar rates of impaired epicardial flow
(TIMI flow grade 0/1/2: 37.3% vs. 34.7%, p  0.7) and
myocardial perfusion (TIMI myocardial perfusion grade
0/1: 52.6% vs. 53.8%, p  0.9) were evident in the culprit
territory among patients with and among those without
elevated BNP, respectively.
Prediction of clinical events. Patients with baseline levels
of BNP80 pg/ml were at significantly higher risk of death
by 30 days after presentation (5.0% vs. 1.2%, p  0.0001).
The higher mortality risk associated with elevated BNP was
evident as early as seven days (2.5% vs. 0.74%, p  0.006)
and persisted through six months of follow-up (p 0.0001,
Fig. 1A). The association between elevated levels of BNP
and mortality at six months was independent of other
important clinical predictors available at presentation, in-
cluding age, gender, diabetes, ST-segment depression, his-
tory of CHF, CHF at presentation, and baseline cTnI result
(odds ratio [OR] 3.3; 95% confidence interval [CI] 1.7 to
6.3). Among patients with UA and no history or clinical
evidence of HF at presentation, elevated levels of BNP were
associated with a threefold higher risk of death through six
months (OR 3.4; 95% CI 1.2 to 9.7) after adjusting for each
these clinical predictors. Moreover, the baseline level of
BNP remained predictive of mortality after the addition of
peak CK-MB (as a measure of infarct size) to the clinical
model (OR 3.3, 95% CI 1.8 to 6.3).
When BNP was evaluated as a semi-continuous variable,
mortality risk increased in a graded fashion with rising levels
of BNP (Fig. 2). As reflected by the respective chi-square
statistics and ORs, the predictive capacity of baseline
measurement of BNP in this population was maximal
between 80 and 120 pg/ml, with a pattern of increasing
mortality risk becoming evident at a concentration of BNP
80 pg/ml (Fig. 2). Although the chi-square statistic was
slightly higher at a threshold of 100 pg/ml, this difference in
discriminatory capacity did not achieve statistical signifi-
cance compared with 80 pg/ml (likelihood ratio test chi-
square  1.84, p  0.9). Five percent (n  83) of
the population had BNP levels between 80 pg/ml and
100 pg/ml.
Increasing levels of BNP (by quartile) were associated
with, at most, a weak trend toward higher risk of recurrent
ischemic events (Table 2). At a decision limit of 80 pg/ml,
BNP was not predictive of an increased risk for new/
recurrent MI (5.3% vs. 5.2%, p  1.0) or rehospitalization
for ACS (13.4% vs. 12.2%, p  0.6) through six months of
follow-up. In contrast, patients with elevated BNP at
presentation had a nearly sixfold higher risk of developing
new or worsening CHF by 30 days (5.9% vs. 1.0%, p 
0.0001), including those with UA (2.9% vs. 0.1%, p 
0.0001). The predictive association between baseline levels
of BNP and CHF persisted at six months (9.1% vs. 1.8%,
Table 1. Univariate Associations With Elevated Levels of BNP
BNP < 80 pg/ml
(n  1,356)
BNP > 80 pg/ml
(n  320) p Value
Demographics
Age, yrs 60 (52, 69) 69 (61, 76)  0.0001
Age 65 yrs 33.8 62.7  0.0001
Female 31.2 43.4  0.0001
Risk factors
Smoking status
Current 28.8 24.1 0.1
Past 38.2 41.4 0.3
Diabetes 25.4 33.8 0.003
History of hypertension 64.8 70.0 0.08
Cardiovascular history
Prior MI 38.7 41.3 0.4
Prior HF 3.9 16.9  0.001
Peripheral vascular disease 6.8 9.7 0.07
Cerebrovascular disease 5.3 6.6 0.4
Prior PCI 30.4 17.8  0.001
Prior CABG 21.6 22.2 0.8
Presenting characteristics
Heart rate, beats/min 73 (64, 82) 75 (65, 88) 0.02
Heart rate 100 beats/min 4.8 10.0 0.001
Systolic BP, mm Hg 133 (120, 150) 135 (120, 156) 0.1
Systolic BP 100 mm Hg 2.7 2.2 0.6
ST depression 1.0 mm 19.0 27.8  0.001
Index diagnosis MI 33.6 47.8  0.001
Data are shown as n (%) for dichotomous variables and median (25th, 75th percentile) for continuous variables.
BNP  B-type natriuretic peptide; BP  blood pressure; CABG  coronary artery bypass grafting; HF  heart failure;
MI  myocardial infarction; PCI  percutaneous interventions.
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p  0.0001) and was independent of the patient’s age,
history of HF, ST deviation, or baseline troponin result
(OR 3.0; 95% CI 1.6 to 5.7). As such, a baseline level of
BNP 80 pg/ml was a strong, independent predictor of
death or CHF at six months after presentation (16.3% vs.
3.6%, adjusted OR 3.2; 95% CI 2.0 to 5.1, Fig. 1B).
Stratification by BNP and troponin results. Consistent
with previous work in TACTICS-TIMI 18 (16), an ele-
vated level of cTnI at presentation was an important
predictor of death (3.8% vs. 1.8%, p  0.02) and MI (6.4%
vs. 3.2%, p  0.004) by six months in the subset of patients
with data on BNP. B-type natriuretic peptide measure-
ments added significant prognostic information to cTnI,
discriminating patients at 4-fold higher mortality risk
among those with both negative (OR 6.9; 95% CI 1.9 to
25.8) and positive (OR 4.1; 95% CI 1.9 to 9.0) baseline
cTnI results (Fig. 3, left). Specifically, among patients with
cTnI 0.1 ng/ml, those with a BNP level 80 pg/ml were
at significantly higher risk of death through 30 days (4.5%
vs. 0.7%, p  0.004) and six months (7.5% vs. 1.2%, p 
0.0003). B-type natriuretic peptide results (dichotomized at
80 pg/ml) did not substantially alter the risk estimates for
recurrent MI among patients either with (4.6% vs. 5.3%,
p  0.6) or without (3.0% vs. 1.7%, p  0.4) elevated levels
of cTnI. Thus, use of BNP and cTnI in combination
enabled identification of patients with negative BNP or
troponin who were at increased risk of death or MI (Fig. 3,
right). Specifically, among patients with a negative cTnI
Figure 2. Mortality risk stratified by B-type natriuretic peptide (BNP) levels over range of 40 to 160 pg/ml. The odds ratio (ORs) and chi-squared (2)
statistics in the table below the chart are based on BNP results dichotomized at the lower bound of the range.
Table 2. Risk of Cardiac Events Through Six Months Stratified by Quartile of Elevated BNP
Quartile of BNP
p Value†0* 1 2 3 4
BNP (pg/ml)  5 5–21 21–42 42–83  83 —
N 448 320 300 304 304 —
New or recurrent MI 4.6 4.4 5.7 6.9 5.3 0.6
Rehospitalization for ACS 11.8 10.0 13.3 14.1 13.5 0.5
HF 1.3 1.9 2.7 1.6 9.5  0.0001
Death or CHF 2.2 4.4 4.7 4.0 16.8  0.0001
Data reported as event rates (%). *Patients with BNP levels below the detection limit of the assay. †Based on chi-square for trend.
ACS  acute coronary syndrome; BNP  B-type natriuretic peptide; CHF  congestive heart failure; HF  heart failure;
MI  myocardial infarction.
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who had elevated BNP, the risk of death or MI was 7.5%;
whereas in those with a negative BNP detected as being at
higher risk only by cTnI, the risk of death or MI through 30
days was 6.4%. Patients with both a negative BNP and cTnI
were at very low risk of death (0.7%) or of death or MI (2.0%).
B-type natriuretic peptide also added important informa-
tion to cTnI for predicting the risk of CHF (Fig. 4). In
contrast with assessment of the risk for recurrent MI,
patients with elevated BNP were at significantly higher risk
of CHF and death or CHF, regardless of troponin status.
Although in multivariable analysis cTnI contributed inde-
pendent information with respect to the risk of CHF (OR
3.4; 95% CI 1.2 to 10.2) and of death or CHF (OR 2.1;
95% CI 1.04 to 4.20), BNP tended toward a stronger
association with each of these end points (OR 3.9, 95% CI
1.7 to 9.1 for CHF and OR 3.3, 95% CI 1.8 to 6.0 for death
or CHF).
Effect of management strategy. Consistent with the pri-
mary results of TACTICS-TIMI 18, among the subset of
patients with BNP data, the invasive management strategy
conferred a 30% relative reduction in the risk of death or MI
(OR 0.70; 95% CI 0.46 to 1.04) and a 23% reduction in the
risk of the primary composite endpoint of death, MI, or
rehospitalization for ACS at six months (OR 0.77; 95% CI
0.60 to 1.0) compared with the conservative strategy. When
results were stratified by baseline BNP, no appreciable
difference was observed in the effect of invasive versus
conservative management among patients with higher levels
of BNP (pinteraction  0.6, Table 3). Stratification by both
cTnI and BNP revealed a pattern of reduced risk of death or
Figure 3. Risk of death or myocardial infarction (MI) at 30 days stratified by B-type natriuretic peptide (BNP) and cardiac troponin I (cTnI). NEG 
negative; POS  positive.
Figure 4. Risk of congestive heart failure (CHF) at 30 days stratified by B-type natriuretic peptide (BNP) and cardiac troponin I (cTnI). NEG  negative;
POS  positive.
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recurrent ischemic events with the invasive strategy among
those with elevated cTnI, regardless of BNP status (Fig. 5).
DISCUSSION
As a putative measure of the hemodynamic consequences of
acute myocardial ischemia and infarction, BNP is a biomar-
ker that has recently shown promise for risk assessment
among patients with non–ST-elevation ACS (12,17,18).
We now have confirmed prospectively our initial retrospec-
tive observations that BNP is a novel marker of increased
risk of death and CHF in patients presenting with UA and
NSTEMI (with or without CHF). In addition, our data
provide new insights into the prognostic relationships be-
tween BNP and individual clinical outcomes that will be
valuable in guiding clinical use of this marker. Specifically,
we have demonstrated a strong association between the
plasma concentration of BNP at presentation and subse-
quent mortality or new CHF in an independent population
of patients with UA and NSTEMI. Moreover, we have
demonstrated that our prospectively defined decision limit
of 80 pg/ml with this assay appears to be a threshold above
which mortality risk begins to increase in ACS. This study
also reveals variation in the relative predictive capacity of
BNP and troponin with respect to individual clinical end
points, with BNP exhibiting a stronger relationship with
death and CHF, and cardiac troponin being predictive of
death and recurrent ischemic events. It is likely that this
difference accounts in part for differences in the ability of
these markers to predict response to a specific therapy, such
as an early invasive management strategy. When used
together in a combined strategy, these two markers provide
a more effective tool for identifying patients at increased risk
for clinically important recurrent cardiac events related to
both ischemia and HF. Such information is likely to
enhance our ability to appropriately triage higher-risk pa-
tients and more reliably identify low-risk patients who may
be candidates for less intensive evaluation and therapy.
At this time, the implications of elevated BNP for
decisions regarding therapy in ACS are not as clear. We
found no interaction between BNP and the effect of the
early invasive management strategy. These results are not
entirely unexpected when one considers that BNP appears
to be a stronger predictor of mortality and HF than of
recurrent non-fatal ischemic events and that the benefit of
the early invasive strategy in this study accrued primarily
from a reduction in recurrent ischemic events. These find-
ings contrast with those for cardiac troponin, which is a
strong predictor of benefit from early invasive management,
and provide direct evidence that different biomarkers carry
different implications for therapy (13,16). Further investi-
gation is needed to identify therapies that may favorably
modify the risk associated with increased levels of BNP in
ACS.
Table 3. Effect of Invasive Versus Conservative Management on
Outcomes at Six months Stratified by BNP Level
INV CON
OR
(95% CI)
p Value for
Interaction
Mortality
BNP 80 pg/ml 7.9 9.0 0.87 (0.4–1.9) 0.6
BNP 80 pg/ml 1.9 1.6 1.2 (0.5–2.7)
Death, MI or
rehospitalization
for ACS
BNP 80 pg/ml 18.3 26.3 0.63 (0.4–1.1) 0.8
BNP 80 pg/ml 14.7 17.3 0.82 (0.6–1.1)
Data reported as event rates (%).
ACS  acute coronary syndrome; BNP  B-type natriuretic peptide; CI 
confidence interval; CON  conservative management; INV  invasive manage-
ment; MI  myocardial infarction; OR  odds ratio.
Figure 5. Effect of the invasive (INV) versus conservative (CON) management strategy stratified by baseline levels of B-type natriuretic peptide (BNP) and
cardiac troponin I (cTnI). ACS  acute coronary syndrome; NEG  negative; POS  positive.
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Additional research is also needed to elucidate the patho-
biologic connections between elevated levels of BNP and
the associated higher mortality risk observed in patients
with non–ST-elevation ACS. We may, however, speculate
as to potential mechanisms (19). Data from both experi-
mental and clinical studies suggest that the plasma level of
BNP may reflect the size or severity of the ischemic insult,
even in the absence of myocardial necrosis. Specifically, in
human models of ischemia, BNP levels have been shown to
increase transiently both after exercise in patients with stable
coronary disease (20) and after uncomplicated coronary
angioplasty, despite stable intracardiac filling pressures
(21,22). Others have shown the rise in the level of BNP to
correlate with the size of an ischemic territory during
nuclear stress imaging (23). B-type natriuretic peptide also
appears to provide a very sensitive tool for detecting early
CHF (24) and may serve to identify patients with unsus-
pected adverse hemodynamic consequences of coronary
ischemia. As such, the available evidence supports a plausi-
ble relationship between BNP and the extent of the isch-
emic territory as a possible link to the increased risk of CHF
and fatal complications. It is interesting that there does not
appear to be a stronger association with future ischemic
events or a more profound benefit from revascularization.
Study limitations. The results of this study address the use
of BNP for risk assessment in patients with a high clinical
probability of ACS. Additional investigation will be neces-
sary to explore the utility of BNP in a broad spectrum of
patients presenting with chest pain and low-to-intermediate
probability of ACS. B-type natriuretic peptide levels may be
elevated in a number of other cardiac and some non-cardiac
conditions (25) and, as with cardiac troponin, must be
integrated with findings from the history and physical
examination to arrive at an overall diagnostic and prognostic
assessment. Nevertheless, data from Jernberg and colleagues
(18) using N-terminal pro-BNP for risk stratification
among a less-selected population of patients admitted to a
coronary care unit support the utility of measuring BNP
and/or its pro-hormone fragments in the general population
with suspected ACS.
This study provides support for interpretation of BNP as
a dichotomous result at 80 pg/ml. However, given a
stepwise relationship between increasing levels of BNP and
mortality risk, the absolute plasma concentration of BNP
carries additional information with respect to the magnitude
of risk that should be considered by the clinician. Never-
theless, for convenient clinical use, a decision limit of 80
pg/ml provides robust predictive capacity with respect to
mortality and CHF and is now supported by two indepen-
dent data sets. This threshold is also qualitatively very
similar to that established for the diagnosis of CHF (100
pg/ml) in a recent prospective study (24).
B-type natriuretic peptide levels change over time after
presentation, and the association with clinical risk may vary
based on the time of ascertainment. It would also be
interesting to have data regarding the serial changes in BNP
concentration among patients presenting with ischemia
without necrosis. Only a baseline sample was obtained for
core lab analysis in TACTICS-TIMI 18, and thus we
cannot comment on the optimal timing of BNP measure-
ment or kinetics of this marker on the basis of our data.
However, we have extended beyond previous findings in
which BNP was measured at one to three days after
presentation to now demonstrate that elevated levels of
BNP at presentation are also associated with adverse out-
comes. It is possible that serial measurements may improve
the prognostic performance of BNP.
Conclusions. An elevated plasma concentration of BNP
(80 pg/ml) at presentation in patients with UA and
NSTEMI predicts higher short- and long-term mortality as
well as new-onset CHF. B-type natriuretic peptide adds
substantially to risk assessment for mortality based on
cardiac troponin alone, but it did not enhance selection of
appropriate candidates for early invasive evaluation in this
study. These findings may be used to guide clinical use of
BNP for risk assessment and triage in patients with sus-
pected ACS. Additional work is needed to identify specific
therapies that may reduce the risk associated with increased
BNP.
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